CY1111565T1 - Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11 - Google Patents
Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11Info
- Publication number
- CY1111565T1 CY1111565T1 CY20111100565T CY111100565T CY1111565T1 CY 1111565 T1 CY1111565 T1 CY 1111565T1 CY 20111100565 T CY20111100565 T CY 20111100565T CY 111100565 T CY111100565 T CY 111100565T CY 1111565 T1 CY1111565 T1 CY 1111565T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cpt
- combination
- combination treatment
- cancer
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε μία μέθοδο για την παραγωγή μίας αντιαγγειογενετικής επίδρασης και/ή επίδρασης μείωσης της αγγειακής διαπερατότητας σε ένα θερμόαιμο ζώο όπως είναι ένας άνθρωπος, που προαιρετικά υποβάλλεται σε θεραπεία με ιονίζουσα ακτινοβολία, ειδικότερα σε μία μέθοδο για τη θεραπευτική αντιμετώπιση ενός καρκίνου, ειδικότερα ενός καρκίνου που συμπεριλαμβάνει έναν συμπαγή όγκο, η οποία περιλαμβάνει μία από τις εξής: τη χορήγηση του ZD6474 σε συνδυασμό με την 5-FU ˙ τη χορήγηση του ZD6474 σε συνδυασμό με την CPT-11 ˙ και τη χορήγηση του ZD6474 σε συνδυασμό με την 5-FU και την CPT-11 ˙ σε μία φαρμακευτική σύνθεση που περιλαμβάνει ένα από τα εξής: ZD6474 και 5-FU ˙ ZD6474 και CPT-11 ˙ και ZD6474 και 5-FU και CPT-11 ˙ σε ένα προϊόν συνδυασμού που περιέχει ένα από τα εξής: ZD6474 και 5-FU ˙ ZD6474 και CPT-11 ˙ και ZD6474 και 5-FU και CPT-11, για χρήση, με θεραπεία, σε μία μέθοδο θεραπευτικής αντιμετώπισης σε σώμα ανθρώπου ή ζώου ˙ σε ένα κιτ που περιλαμβάνει ένα από τα εξής: ZD6474 και 5-FU ˙ ZD6474 και CPT-11 ˙ και ZD6474 και 5-FU και CPT-11 ˙ στη χρήση ενός από τα εξής: ZD6474 και 5-FU ˙ ZD6474 και CPT-11 ˙ και ZD6474 και 5-FU και CPT-11, στην παρασκευή ενός φαρμάκου για χρήση στην παραγωγή ενός αντιαγγειογενετικού αποτελέσματος και/ή ενός αποτελέσματος μείωσης της αγγειακής διαπερατότητας σε ένα θερμόαιμο ζώο όπως είναι ένας άνθρωπος, που προαιρετικά υποβάλλεται σε θεραπεία με ιονίζουσα ακτινοβολία.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0303289A GB0303289D0 (en) | 2003-02-13 | 2003-02-13 | Combination therapy |
GB0314100A GB0314100D0 (en) | 2003-06-18 | 2003-06-18 | Combination therapy |
GB0316184A GB0316184D0 (en) | 2003-07-10 | 2003-07-10 | Combination therapy |
GB0318311A GB0318311D0 (en) | 2003-08-05 | 2003-08-05 | Combination therapy |
EP04710081A EP1592423B1 (en) | 2003-02-13 | 2004-02-11 | Combination therapy of zd6474 with 5-fu and/or cpt-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1111565T1 true CY1111565T1 (el) | 2015-10-07 |
Family
ID=32872851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20111100565T CY1111565T1 (el) | 2003-02-13 | 2011-06-15 | Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11 |
Country Status (18)
Country | Link |
---|---|
US (4) | US20060142316A1 (el) |
EP (1) | EP1592423B1 (el) |
JP (3) | JP2006517575A (el) |
KR (2) | KR20110006699A (el) |
AT (1) | ATE506062T1 (el) |
AU (1) | AU2004212255B2 (el) |
CA (1) | CA2514227C (el) |
CY (1) | CY1111565T1 (el) |
DE (1) | DE602004032310D1 (el) |
DK (1) | DK1592423T3 (el) |
HK (1) | HK1084032A1 (el) |
IL (1) | IL169702A (el) |
MX (1) | MXPA05008583A (el) |
NO (1) | NO331486B1 (el) |
NZ (1) | NZ541297A (el) |
PT (1) | PT1592423E (el) |
SI (1) | SI1592423T1 (el) |
WO (1) | WO2004071397A2 (el) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA72946C2 (uk) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
RU2350618C2 (ru) | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
JP2006517575A (ja) * | 2003-02-13 | 2006-07-27 | アストラゼネカ アクチボラグ | 組合せ療法 |
GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
DE602004028834D1 (de) * | 2003-07-10 | 2010-10-07 | Astrazeneca Ab | Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität |
WO2005117980A1 (en) * | 2004-06-04 | 2005-12-15 | Pfizer Products Inc. | Method for treating abnormal cell growth |
BRPI0516052A (pt) * | 2004-09-27 | 2008-08-19 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
JP5167144B2 (ja) * | 2005-12-22 | 2013-03-21 | アストラゼネカ アクチボラグ | 併用療法 |
WO2008037996A1 (en) * | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Combination of zd6474 and bevacizumab for cancer therapy |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA72946C2 (uk) * | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
GB0008269D0 (en) * | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
GB0218526D0 (en) * | 2002-08-09 | 2002-09-18 | Astrazeneca Ab | Combination therapy |
CA2495487A1 (en) * | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer |
GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
JP2006517575A (ja) * | 2003-02-13 | 2006-07-27 | アストラゼネカ アクチボラグ | 組合せ療法 |
DE602004028834D1 (de) * | 2003-07-10 | 2010-10-07 | Astrazeneca Ab | Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität |
BRPI0516052A (pt) * | 2004-09-27 | 2008-08-19 | Astrazeneca Ab | uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente |
GB0424339D0 (en) * | 2004-11-03 | 2004-12-08 | Astrazeneca Ab | Combination therapy |
JP4834985B2 (ja) * | 2004-12-10 | 2011-12-14 | 日産自動車株式会社 | 組電池の容量調整装置 |
JP5167144B2 (ja) * | 2005-12-22 | 2013-03-21 | アストラゼネカ アクチボラグ | 併用療法 |
WO2008037996A1 (en) * | 2006-09-29 | 2008-04-03 | Astrazeneca Ab | Combination of zd6474 and bevacizumab for cancer therapy |
-
2004
- 2004-02-11 JP JP2006502268A patent/JP2006517575A/ja not_active Withdrawn
- 2004-02-11 PT PT04710081T patent/PT1592423E/pt unknown
- 2004-02-11 CA CA2514227A patent/CA2514227C/en not_active Expired - Fee Related
- 2004-02-11 MX MXPA05008583A patent/MXPA05008583A/es active IP Right Grant
- 2004-02-11 AT AT04710081T patent/ATE506062T1/de active
- 2004-02-11 DK DK04710081.3T patent/DK1592423T3/da active
- 2004-02-11 DE DE602004032310T patent/DE602004032310D1/de not_active Expired - Lifetime
- 2004-02-11 AU AU2004212255A patent/AU2004212255B2/en not_active Ceased
- 2004-02-11 KR KR1020107027024A patent/KR20110006699A/ko not_active Application Discontinuation
- 2004-02-11 KR KR1020057014913A patent/KR20050100683A/ko active Search and Examination
- 2004-02-11 US US10/543,106 patent/US20060142316A1/en not_active Abandoned
- 2004-02-11 EP EP04710081A patent/EP1592423B1/en not_active Expired - Lifetime
- 2004-02-11 NZ NZ541297A patent/NZ541297A/en not_active IP Right Cessation
- 2004-02-11 WO PCT/GB2004/000550 patent/WO2004071397A2/en active IP Right Grant
- 2004-02-11 SI SI200431690T patent/SI1592423T1/sl unknown
-
2005
- 2005-07-17 IL IL169702A patent/IL169702A/en not_active IP Right Cessation
- 2005-07-27 NO NO20053649A patent/NO331486B1/no not_active IP Right Cessation
-
2006
- 2006-04-11 HK HK06104405.5A patent/HK1084032A1/xx not_active IP Right Cessation
-
2009
- 2009-07-13 US US12/501,599 patent/US20100130520A1/en not_active Abandoned
-
2010
- 2010-10-25 JP JP2010238996A patent/JP5563950B2/ja not_active Expired - Fee Related
- 2010-12-20 US US12/973,271 patent/US20110086870A1/en not_active Abandoned
-
2011
- 2011-06-15 CY CY20111100565T patent/CY1111565T1/el unknown
- 2011-10-27 US US13/282,750 patent/US20120252826A1/en not_active Abandoned
-
2014
- 2014-01-23 JP JP2014010618A patent/JP2014065750A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20110006699A (ko) | 2011-01-20 |
JP2011016853A (ja) | 2011-01-27 |
MXPA05008583A (es) | 2005-11-04 |
CA2514227A1 (en) | 2004-08-26 |
PT1592423E (pt) | 2011-06-16 |
DK1592423T3 (da) | 2011-06-27 |
NO331486B1 (no) | 2012-01-16 |
AU2004212255A1 (en) | 2004-08-26 |
NO20053649D0 (no) | 2005-07-27 |
JP2006517575A (ja) | 2006-07-27 |
KR20050100683A (ko) | 2005-10-19 |
JP5563950B2 (ja) | 2014-07-30 |
HK1084032A1 (en) | 2006-07-21 |
EP1592423B1 (en) | 2011-04-20 |
IL169702A (en) | 2014-05-28 |
EP1592423A2 (en) | 2005-11-09 |
WO2004071397A2 (en) | 2004-08-26 |
NO20053649L (no) | 2005-09-12 |
US20110086870A1 (en) | 2011-04-14 |
CA2514227C (en) | 2011-08-09 |
WO2004071397A3 (en) | 2004-10-14 |
US20100130520A1 (en) | 2010-05-27 |
SI1592423T1 (sl) | 2011-07-29 |
ATE506062T1 (de) | 2011-05-15 |
IL169702A0 (en) | 2007-07-04 |
US20120252826A1 (en) | 2012-10-04 |
AU2004212255B2 (en) | 2007-07-05 |
US20060142316A1 (en) | 2006-06-29 |
DE602004032310D1 (de) | 2011-06-01 |
JP2014065750A (ja) | 2014-04-17 |
NZ541297A (en) | 2008-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1111565T1 (el) | Θεραπεια συνδυασμου του zd6474 με 5-fu και/ή cpt-11 | |
DK1551409T3 (da) | Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer | |
DK1971338T3 (da) | Kombination af ZD6474 og pemetrexed | |
MX2007003505A (es) | Combinacion que comprende zd6474 e imatinib. | |
NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
CY1111482T1 (el) | Συνδυασμος azd2171 και πεμετρεξεδης | |
NO20056170L (no) | Kreftkombinasjonsterapi omfattende AZD2171 of ZD1839 | |
NO20064755L (no) | Kombinasjonsterapi | |
NO20056171L (no) | Kombinasjonsterapi | |
NO20064754L (no) | Kombinasjonsterapi | |
MXPA05013827A (es) | Composiciones que comprenden zd6126 junto con 5-fu, cpt-11 o 5-fu y cpt-11, que tienen actividad de dano vascular, para tratar cancer colorectal e. g. |